MT2019-40: A Phase I, Open-Label, Multicenter Study of FT596 as a Monotherapy and in Combination withRituximab or Obinutuzumab in Subjects with Relapsed/Refractory B-cell Lymphoma and ChronicLymphocytic Leukemia

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.